References:
1. Maron BJ. Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 2007;116(2):196-206; discussion 206.
2. Makhija N, Magoon R, Balakrishnan I, Das S, Malik V, Gharde P. Left ventricular outflow tract obstruction following aortic valve replacement: A review of risk factors, mechanism, and management. Ann Card Anaesth 2019;22(1):1-5.
3. Bartunek J, Sys SU, Rodrigues AC, van Schuerbeeck E, Mortier L, de Bruyne B. Abnormal systolic intraventricular flow velocities after valve replacement for aortic stenosis. Mechanisms, predictive factors, and prognostic significance. Circulation 1996;93(4):712-9.
4. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346(8969):211-4.
5. Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, Bauer F, Greenberg NL, Agler DA, Drinko JK and others. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001;38(7):1994-2000.
6. Kato M, Miyahara M, Suzuki H, Uchida F, Nishimura Y, Nishikawa H. A case of successful percutaneous transluminal septal myocardial ablation for heart failure due to severe left ventricular outflow obstruction with Monckeberg’s arteriosclerosis, manifested after aortic valvular replacement. Cardiovasc Interv Ther 2015;30(1):72-7.